Japan Authorizes Dexamethasone as Covid-19 Treatment as UK Trial Reveals It Lowers Death Rates in Patients
FILE PICTURE: An ampoule of Dexamethasone. REUTERS/Yves Herman/File Photo
Shares of Nichi-Iko Pharmaceutical Co, among those that produce the drug, acquired as much as 6.5%in early trade.
- Reuters Tokyo
- Last Updated: July 22, 2020, 9: 14 AM IST
Japan’s health ministry has authorized dexamethasone, an inexpensive and commonly used steroid, as a 2nd treatment of COVID-19 after a trial in Britain revealed the drug lowered death rates in hospitalised patients.
The ministry consisted of dexamethasone as an option for treatment in addition to Gilead Sciences Inc’s antiviral drug remdesivir in a recent modification to its handbook. The revision was widely reported by Japanese media on Wednesday and was viewed by Reuters.
Shares of Nichi-Iko Pharmaceutical Co, amongst those that produce the drug, acquired as much as 6.5%in early trade.
In results announced last month, a trial by scientists in the United Kingdom revealed dexamethasone as the very first drug to save lives of COVID-19 patients in what scientists stated was a major advancement in the coronavirus pandemic.
The full results of the large randomised medical trial released last Friday in the New England Journal of Medication confirmed the benefits for people with sophisticated or moderate disease.
Comments
Post a Comment